Investing
Oil’s price drop Tuesday to the lowest finish in three-and-a-half months may come as a surprise to traders focused on the risk of crude...
Hi, what are you looking for?
iFintechWorld
iFintechWorld
Investing
U.S. natural-gas supplies in storage marked their biggest weekly decline in nearly three years — but that wasn’t enough to rally prices for the...
Investing
Oil futures rose Thursday to settle at their highest prices since late November after government data showed larger-than-anticipated drops in U.S. crude inventories and...
Investing
Oil prices gave up early losses to finish higher on Friday — with production outages in the U.S., strong economic data and concerns about...
Investing
Casey’s General Stores Inc., the nation’s third-largest convenience store chain, has agreed to acquire 22 Lone Star Food Stores in the Sherman, Texas, area...
Investing
The retail industry faces a reckoning next year when we finally learn the true state of the consumer in a post-Covid world – without...
Investing
By Ben Glickman Shares of Verve Therapeutics surged Tuesday after revenue jumped in the third quarter. The stock was up 29% to $19.31 in...
Investing
Key News Asian equities were mixed overnight on light news. Hong Kong and Mainland China eased off morning gains in the afternoon. Real estate...
Investing
By Will Feuer Kyndryl Holdings narrowed its fiscal second-quarter loss as the provider of information-technology-infrastructure services cut costs ahead of schedule. The company, which...
Investing
When describing the municipal bond market, the first adjectives are usually “staid” or “stodgy”. The terms “data-driven” or “technologically cutting edge” are not usually...
Investing
By Will Feuer Kyndryl Holdings raised its cost-savings targets for the current fiscal year, citing progress using automation to streamline operations and the removal...
Investing
2024 is setting up to be a great year for us contrarian dividend investors—but to take full advantage, we need to buy now—while fear...
Investing
By Denny Jacob Gilead Sciences raised its outlook for 2023. The biopharmaceutical company forecast total sales between $26.7 billion and $26.9 billion versus its...
